Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
110.41
-0.62 (-0.56%)
Jul 1, 2026, 4:00 PM EDT - Market closed
Rhythm Pharmaceuticals Employees
Rhythm Pharmaceuticals had 414 employees as of December 31, 2025. The number of employees increased by 131 or 46.29% compared to the previous year.
Employees
414
Change (1Y)
131
Growth (1Y)
46.29%
Revenue / Employee
$524,553
Profits / Employee
-$502,029
Market Cap
7.57B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 414 | 131 | 46.29% |
| Dec 31, 2024 | 283 | 57 | 25.22% |
| Dec 31, 2023 | 226 | 49 | 27.68% |
| Dec 31, 2022 | 177 | 37 | 26.43% |
| Dec 31, 2021 | 140 | 50 | 55.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Vaxcyte | 507 |
| Mirum Pharmaceuticals | 418 |
| TG Therapeutics | 399 |
| Immunovant | 315 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
RYTM News
- 15 days ago - Rhythm Pharmaceuticals price target raised to $151 from $143 at Canaccord - TheFly
- 16 days ago - Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 - GlobeNewsWire
- 16 days ago - Rhythm Pharmaceuticals price target raised to $155 from $144 at Wells Fargo - TheFly
- 17 days ago - Rhythm announces preliminary data from Phase 2 trial of setmelanotide - TheFly
- 18 days ago - Rhythm Pharmaceuticals Transcript: Study result - Transcripts
- 18 days ago - Rhythm Pharmaceuticals Slides: Study result - Filings
- 18 days ago - Rhythm Pharmaceuticals Press release: Study result - Filings
- 18 days ago - Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 - GlobeNewsWire